Chevalier B., Fumoleau P., Kerbrat P. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322.
Francis P., Schneider J., Hann L. (1994) Phase II trial of docetaxel in patients with platonium-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308.
Fossella F.V., Lee J.S., Murphy W.K. (1994) Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244.
Guillaume J.C., Carp E., Rougier P. (1988) Effets secondaires cutaneomuqueux des perfusions continues de 5-fluorouracile. Ann Dermatol Venereol 115:1167-1169.
Burgdof W., Gilmore W., Ganick R. (1982) Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 97:61-62.
Vanhooteghem O., Andre J., Vindevoghel A. (1997) Docetaxel-induced subungual hemorrhage. Dermatology 194:419-420.
Correia O., Azevedo C., Pinto Ferreira E. (1999) Nail changes secondary to docetaxel (Taxotere). Dermatology 198:288-290.
Begaud B., Evreux J.C., Jouglard J., Lagier G. (1985) Imputabilite des effets inattendus ou toxiques des medicaments. Actualisation de la mehode utilisee en France. Therapie 40:111-118.
